Oral hypomethylating agents: beyond convenience in MDS
EA Griffiths - Hematology, 2021 - ashpublications.org
Oral hypomethylating agents (HMAs) represent a substantial potential boon for patients with
myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per …
myelodysplastic syndrome (MDS) who have previously required between 5 and 7 visits per …